July 28, 2026 Second Quarter 2026 Earnings Presentation Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as…
July 28, 2026
Second Quarter 2026
Earnings Presentation
Disclaimer
Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “hope”, “intend”, “may”,
“might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “strive”, “seeks”, “would”, “will”, “understand” and similar words are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is
not forward looking. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our backlog and order potential, our business strategy and plans, our objectives
for future operations, macroeconomic trends including the trends in cancer care, nuclear power and small modular reactor industries, foreign exchange, interest rate and inflation expectations and any future mergers, acquisitions, divestitures and
strategic investments, including the completion and integration of previously completed transactions. There are a significant number of factors that could cause actual results to differ materially from statements made in this Presentation, including
changes in domestic and foreign business, market, economic, financial, political and legal conditions, including related to matters affecting Russia, the relationship between the United States and China, conflict, hostilities or geopolitical instability in
the Middle East (including the U.S.-Israel-Iran conflict), potential tariffs, sanctions, export controls, trade restrictions or other trade and supply chain disruptions, and risks of slowing economic growth or economic recession in the United States and
globally; developments in the government budgets (defense and non-defense) in the United States and other countries, including budget reductions, sequestration, implementation of spending limits or changes in budgetary priorities, delays in the
government budget process, a U.S. government shutdown or the U.S. government’s failure to raise the debt ceiling; risks related to the public’s perception of nuclear radiation and nuclear technologies; risks related to the continued growth of our end
markets and timing of customer capital spending, procurement timing and project schedules; our ability to win new customers and retain existing customers; our ability to realize sales expected from our backlog of orders and contracts; risks related
to governmental contracts; our ability to mitigate risks associated with long-term fixed price contracts, including risks related to inflation; risks related to information technology system failures or other disruptions or cybersecurity, data security or
other security threats, including risks related to the implementation and enhancement of information systems and emerging technologies such as artificial intelligence; our ability to manage our supply chain or difficulties with third-party
manufacturers; risks related to competition; our ability to manage disruptions of, or changes in, our independent sales representatives, distributors and original equipment manufacturers; our ability to realize the expected benefit from strategic
transactions, such as acquisitions, divestitures, investments and partnerships, including any synergies, or internal restructuring and improvement efforts; our ability to issue debt, equity or equity-linked securities in the future; risks related to changes in
tax law and ongoing tax audits; risks related to future legislation and regulation both in the United States and abroad; risks related to the costs or liabilities associated with product liability claims; risks related to the uncertainty of legal claims,
litigation, arbitration and similar proceedings; our ability to attract, train and retain key members of our leadership team and other qualified personnel; risks related to the adequacy of our insurance coverage; risks related to the global scope of our
operations, including operations in international and emerging markets; risks related to our exposure to fluctuations in foreign currency exchange rates, interest rates and inflation, including the impact on our debt service costs; our ability to comply
with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to our ability to protect or enforce our
proprietary rights on which our business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; our ability to predict our future operational results; and the effects of health
epidemics, pandemics and similar outbreaks may have on our business, results of operations or financial condition. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make
with the United States Securities and Exchange Commission (the “SEC”) from time to time, including our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other periodic reports filed or to be filed with the SEC.
You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements
in this Presentation are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on
which they were made.
Non-GAAP Financial Measures
In addition to our results determined in accordance with GAAP, we believe non-GAAP measures are useful in evaluating our operating performance, including organic revenues, adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted
EPS, adjusted free cash flow, adjusted free cash flow conversion, net leverage. We use this non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial
information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes
only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled
non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. See the footnotes on the slides where these measures
are discussed and the Non-GAAP reconciliations in the Appendix for a description of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures. Additionally, forward-looking non-GAAP financial
measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as
stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control or cannot be reasonably predicted. Accordingly,
a reconciliation for our guidance organic revenue growth, adjusted EBITDA, adjusted earnings per share, adjusted free cash flow, adjusted free cash flow conversion, and net leverage is not available without unreasonable effort.
Industry and Market Data
In this presentation, we rely on and refer to information and statistics regarding market participants in the sectors in which Mirion competes and other industry data. We obtained this information and statistics from third-party sources, including
reports by market research firms and company filings. Mirion has not independently verified the data obtained from these sources and cannot assure you of the data’s accuracy or completeness.
Operating Metrics
This presentation contains certain operating metrics that our management uses to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions, including orders. See the Appendix to
this presentation for our definitions of such metrics.
2
Q2 2026
Earnings Presentation
Mirion
Q2 Key Takeaways
Growing Orders & Backlog;
Large Opportunity Orders Wins
+10% Q2 orders growth; +50% Nuclear
Power end-market (both ex. M&A)
$51M of large opportunities awarded in
Q2; ~$55M already awarded in July2
3
Expanding Adj. EBITDA
Margins
Margin expansion across both Nuclear
& Safety and Medical segments; total
enterprise also expanded
Year-over-year growth numbers reflect comparison vs. Q2’25
1 Excludes the July 2025 Certrec and December 2025 Paragon acquisitions.
2 Part of the large opportunity order pipeline previously disclosed; excludes China de-booking.
Setting the Stage for Second
Half Acceleration
H2’26 performance expected to
be markedly better than H1’26
Maintaining ‘26 guidance; backlog gives
confidence in H2’26 performance
Q2 2026
Earnings Presentation
Growing Opportunities in North America
Well-positioned to capitalize on these opportunities with the Paragon and Certrec acquisitions
UNITED STATES
UNITED STATES
UNITED STATES
$1.4 Trillion Utilities Capex
Through 20301
Long-term Canada Strategy
Calls for 10 New Reactors2
U.S. Department of Energy
Reactor Pilot Program3
U.S. Announces $17.5 Billion
Loan Program for New Nuclear4
+20% increase in projected U.S. electric
utility investment to meet accelerating
electrical demand
Targeting 10 new reactors as part of
Canada’s Nuclear Energy Strategy
Achieved criticality across four
advanced reactor designs; outperformed
a targeted goal of three by July 4th
Supporting the nuclear supply chain in
support of 10 new large-scale nuclear
reactors under construction by 20301
Installed
Base
New
Nuclear
New
Nuclear
SMRs
UNITED STATES
UNITED STATES
U.S. Army Wants to Deploy
Small Nuclear Power Plants6
U.S. / Saudi Arabia Civilian
Nuclear Power Deal6
U.S. NRC Proposes Updates to
Streamline Regulatory Process7
Constellation and Walmart
Announce Nuclear Agreement8
The Janus Program aims to put
commercial reactors into military service
by 2028
New power reactors and other nuclear
technology to be provided by U.S.
companies
Proposed updates eliminate unnecessary
burdens and increase regulatory clarity
while maintaining safety standards
Walmart’s first NPP agreement and is
among the first between a large retailer
and a nuclear energy facility in the U.S.
New
Nuclear
4
CANADA
New
Nuclear
UNITED STATES
UNITED STATES
Installed Base /
New Nuclear
1 Powerlines.org, April 2026; 2 Government of Canada; https://natural-resources.canada.ca/energy-sources/nuclear-energy-uranium/nuclear-energy-strategy-Canada; 3 US DoE;
https://www.energy.gov/articles/department-energy-celebrates-fourth-criticality-ahead-july-4th-goal; 4 US Department of Energy (DoE): https://www.energy.gov/articles/department-energy-announces-americannuclear-supply-chain-loans; 5 Chemical & Engineering News; https://cen.acs.org/energy/nuclear-power/US-Army-deploy-small-nuclear/103/web/2025/10; 6 Wall Street Journal; 7 US Nuclear Regulatory
Commission; https://www.nrc.gov/reading-rm/doc-collections/news/2026/index; 8 Constellation Energy; https://www.constellationenergy.com/news/2026/06/constellation-and-walmart-announce-long-termagreement-to-support-reliable-emissions-free-nuclear-energy-in-illinois.html
Installed
Base
Q2 2026
Earnings Presentation
Growing Projections for Global Nuclear Capacity1
Favorable outlook for Mirion’s global presence
2016 Projections
~1,000 GWe
total global capacity
by 2050
+150% vs. ~400GWe today
2025 Projections
1,428 GWe
total global capacity
by 2050
+257% vs. ~400GWe today
2026 Projections
1,446 GWe
total global capacity
by 2050
+262% vs. ~400GWe today
A 45% Increase Compared to Projections a Decade Ago
5
1 Source: World Nuclear Association
Q2 2026
Earnings Presentation
Three Waves of Installed Base Nuclear Customer Demand
Mirion well-positioned across all three … each independent and additive
2
6
CATCH-UP
CAPITAL SPENDING
LIFE-EXTENSION &
POWER UPRATES
DIGITAL
TRANSFORMATION
Deferred Maintenance
& Replacement Parts
I&C and RP
System Upgrades
AI-Enabled
Digital Platforms
PRIMARY BENEFICIARY
PRIMARY BENEFICIARY
PRIMARY BENEFICIARY
Commercial Grade Dedication (CGD) ·
Reverse Engineering · PeAks
Instrumentation and Controls (I&C) ·
Reactor Protection Systems (RPS) · 10–20 yr fieldable life
• Two decades of capital rationing created a massive
backlog of deferred repairs and replacements
• A decision to life-extend triggers mandatory
upgrades to I&C and radiation protection systems
• Nuclear power plant restarts create an additional
funnel for catch-up capital spending
• NRC compliance and power uprate requirements
create demand across the operating fleet
Institutional knowledge replacement ·
Outage optimization · Thermal efficiency
• Retiring workforce erodes institutional knowledge;
operators need digital platforms to capture and scale
expertise
• Shorter outages and higher thermal output through
AI-enabled digitization
Q2 2026
Earnings Presentation
Q2’26 vs. Q2’25
Backlog
+39%
+17%
Total
Company
Excl.
M&A
$ millions
Expanding Backlog
Reflects Orders
Momentum
$825
7
$812
$814
$819
$1,121
$1,139
$148
$153
$178
M&A
$956
$967
$961
Total
Excl.
M&A
Q4’25
Q1’26
Q2’26
$816
$13
$803
Q2’24
Precursor to Accelerated
Revenue Growth
$815
$1,104
Q3’24
Q4’24
Q1’25
Q2’25
Q3’25
Stable Revenue
Visibility from Backlog
Nuclear Power
Dominated
Installed Base
Leading the Way
Q2’26 backlog shows
similar revenue
visibility vs. prior years
63% of backlog
related to the Nuclear
Power end-market
Q2’26 Installed Base
backlog (excl. M&A) of
$312M, +39% YoY
Backlog figures on an as reported basis. Total backlog figures include acquisitions of Certrec, and Paragon Energy
Solutions.
Q2 2026
Earnings Presentation
Revenue Visibility from Backlog
Q2’26 backlog shows similar revenue visibility vs. prior years
$1,129 - $1,147M
$801M
FY’23
Revenue
$273M
H2’23
backlog
conversion
$861M
FY’24
Revenue
$910M
FY’26E
Revenue2
81%
FY’25
Adj. Revenue1
$399M
$288M
H2’24
backlog
conversion
$300M
H2’25
backlog
conversion
H2’26
backlog
conversion
$379M
$400M
$425M
$524M
Q2 2023
Q2 2024
Q2 2025
Q2 2026
81%
80%
80%
81%
H1’23
revenue
FY’23E
Revenue
Coverage
H1’24
revenue
FY’24E
Revenue
Coverage
H1’25
revenue
FY’25E
Adj. Revenue
Coverage1
H1’26
revenue
FY’26E
Revenue
Coverage
at the mid-point
of guidance
8
1 FY’25 Adjusted Revenue excludes M&A (Paragon & Certrec) because both were not part of the H2’25 backlog as of June 30, 2025.
2 Revenue range reflects 2026 total revenue growth guidance.
2026 Revenue
Coverage
Similar revenue visibility
to prior years
Confidence in H2’26
Performance
Well-positioned for second
half revenue growth
PeAks Revenue
Paragon revenue stream that
does not appear in backlog
(additive to our coverage
dynamics)
Q2 2026
Earnings Presentation
Incorporating AI Across Mirion
Dedicated resources to accelerate adoption and deployment
Accelerating Product
Development
9
Organization-wide
Efficiencies
AI-powered
Solutions
•
Faster software development cycles
(from months to days)
•
Optimization of manufacturing and
supply chain
•
New AI-centric innovations across
Nuclear & Safety and Medical
•
Improved data analytics and realtime feedback
•
Automation of back-office
processes
•
Connecting Mirion hardware devices
to drive customer productivity
•
Automated and quicker testing and
compliance
•
Unifying data across Mirion’s global
operations
•
Expand into previously untapped
revenue streams
Q2 2026
Earnings Presentation
organic vs. Q2’25;
$266.8M +1.2%
+19.7% total; highlights demand
Q2’26 Revenue
Q2 Performance
Highlights
+27.5% vs. Q2’25;
$65.3M
Q2’26 adj. EBITDA
~+150bps of margin expansion;
~+200bps excluding M&A
and tariff refund
$25M
~1.4 million shares
repurchased in Q2’26;
Q2’26 shares
repurchased
10
from the Paragon and RTQA
end-markets
$40 million remaining under our
share repurchase program
For a reconciliation of non-GAAP financial measures to the most
directly comparable GAAP measures, please see the Appendix.
$49M Q2 Adj. FCF
Generation
Reflecting strong operating
performance and source of
cash from net working
capital
Strong Q2 Orders
+10% vs. Q2’25; excluding
M&A. +40% including M&A.
Reflect growing N. America
nuclear power demand
Q2 2026
Earnings Presentation
2026 Large Opportunity Pipeline1
~$280 Million of Incremental Opportunity Still Available in ‘26
Q1
Q2
Small Modular
Reactors
Radioactive
Waste
Operating Fleet
Reactors
Radiation
Cameras
First portion
First portion
Safety-critical
qualification
RTQA Medical
Order
Small Modular
Reactors
Radioactive
Waste
Small Modular
Reactors
Second portion
Second portion;
more to come
First portion; more
to come
$53M
~15 total
reactors
$51M
No impact on
2026 guidance
Q3
to date
European
Operating Fleet
Labs &
DoE
Booked in July
Booked in July
China New Build
De-booking
Year To Date Awards
11
1 Large opportunity pipeline projects are $10 million or more.
2 NPP = large-scale nuclear power plants; SMR = small modular reactor.
Booked in 2019
12
Large
opportunity
pipeline
in-queue
~$55M
~$37M less China de-booking
~$159M
~$141M less China de-booking
8
2
2
New build
opportunities
Includes large-scale nuclear power
plants (all non-U.S.) & SMRs2
Installed base
opportunities
Other
opportunities
2027 Opportunities Growing
Q2 2026
Earnings Presentation
Q2’26 Orders Performance (vs. Q2’25)
KEY TAKEAWAYS:
Delivering on the Large Opportunity Pipeline
2nd Quarter 2026
Nuclear & Safety
segment orders driven
by Nuclear Power
installed base and SMRs
+58%
+10%
+40%
Order Growth,
excl. Paragon & Certrec
acquisitions
$62M
$24M
$328M
($18M)
$291M
Lower RTQA (primarily China)
and dosimetry orders; flat
nuclear medicine orders
$229M
($3M)
$208M
Includes large SMR
order awarded in
April
Includes large
opportunity orders
Q2’25
Order Book
$55M
Total Order
Growth
including 2 large orders
booked in early July
+
China de-booking
Nuclear
& Safety
Segment
Medical
Segment
Q2’26
Order Book
Excluding
Paragon & Certrec
Acquisitions
Paragon +
Certrec
Acquisitions1
Q2’26
Order Book
Including
Paragon & Certrec
Acquisitions
Early July Large
Opportunity
Awards
China
De-booking
Nuclear & Safety
segment
12
Orders figures on an ‘as reported’ basis.
1 Paragon acquisition closed in December 2025. This is the second full quarter of Paragon being included in Mirion’s financial and operational results.
Q2’26 Order
Book + Early
July Large
Opportunity
Awards +
China Debooking
China de-booking has no
impact on 2026 guidance
Q2 2026
Earnings Presentation
Q2’26 Orders Performance (vs. Q1’26)
Timing of large opportunity awards impacted expected performance
+14%
$55M
+1%
$15M
including 2 large orders
booked in early July
+
China de-booking
$328M
Total Order
Growth
($18M)
$291M
$288M
($12M)
Includes Paragon &
Cetrec acquisitions
Q1’26
Order Book
Nuclear & Safety
Segment
Positive excluding
large order from
OEM sector in Q1’26
Medical
Segment
Q2’26
Order Book
Including Paragon &
Certrec Acquisitions
Early July Large
Opportunity Awards
China
De-booking
Q2’26 Order Book + Early
July Large Opportunity
Awards + China De-booking
Below Q2 orders guidance of +15 – 20%; slight miss including $18M July unplanned de-booking + two large orders awarded in early July
13
Orders figures on an ‘as reported’ basis. Both Q1’26 and Q2’26 include Paragon and Certrec orders on a reported, like-for-like basis.
Q2 2026
Earnings Presentation
Growing Nuclear Power Momentum
Remain Confident in our Double-digit Organic Revenue Growth Projection
Nuclear Power End-market
+1%
+50%
$49M
SMR-related Orders
Revenue Growth
excl. M&A1
+$42M Q2’26 vs. Q2’25
excl. M&A1
$64M YTD SMR-related orders
flat organic revenue
Order Growth
Q2’26 vs. Q2’25
+47% excluding FX
Q2’26 vs. Q2’25
1 Excludes the July 2025 Certrec and December 2025 Paragon acquisitions.
14
Q2 2026
Earnings Presentation
Mirion
Second Quarter Ended June 30, 2026
Revenue
Adjusted EBITDA and Margin1
Adjusted diluted EPS2
$ millions | % percentage
$ millions | % percentage
$ cents
%
Q2’26 vs.
Q2’25
Organic
+1.2%
Acquisition
+17.9%
FX
+0.6%
Total
+19.7%
$0.09
per share
+19.7%
+27.5%
$266.8
Q2’25
15
+9.1%
$65.3
$222.9
includes stock-based
compensation; similar
comparison to Q2’26
Adjusted diluted EPS;
$0.11
$0.12
$51.2
Q2’26
Adjusted
EBITDA
Margin:
Q2’25
Q2’26
23.0%
24.5%
For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q2 2025 and Q2 2026 are to the three months ended June 30, 2025 and 2026, respectively.
1 Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.
2 Q1’26 is the initial quarter that we are including stock-based compensation in the Adjusted EPS calculation. Note, Q2’25 is excluding stock-based compensation.
Q2’25
Q2’26
Q2 2026
Earnings Presentation
NUCLEAR & SAFETY
Mirion Nuclear & Safety
Second Quarter Ended June 30, 2026
KEY TAKEAWAYS:
Revenue
Adjusted EBITDA and Margin1
$ millions | % percentage
$ millions | % percentage
%
Paragon continues
delivering2
Revenue Growth
• +15% vs Q2’25
• +27% vs 1H’25
Q2’26 vs.
Q2’25
Organic
+2.3%
Acquisition
+28.1%
FX
+1.0%
Total
+31.4%
+31.4%
+34.6%
$186.2
$51.0
$141.7
Q2’25
16
2nd Quarter 2026
$37.9
Q2’26
Adjusted
EBITDA
Margin:
Q2’25
Q2’26
26.7%
27.4%
For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q2 2025 and Q2 2026 are to the three months ended June 30, 2025 and 2026, respectively.
1 Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.
2 Paragon financial performance reflects unaudited condensed consolidated financial statements
Flat Nuclear Power endmarket organic revenue;
SMRs and installed base
growth offset by new build
decline
Adj. EBITDA margin
increased driven by favorable
product mix in Europe and
one-time tariff refund benefit;
helping to offset M&A dilution
Q2 2026
Earnings Presentation
MEDICAL
Mirion Medical
Second Quarter Ended June 30, 2026
KEY TAKEAWAYS:
Revenue
Adjusted EBITDA and Margin1
$ millions | % percentage
$ millions | % percentage
%
Q2’26 vs.
Q2’25
Organic
(0.9%)
Acquisition
n/a
FX
+0.2%
Total
(0.7%)
RTQA organic revenue
growth driven by OEM
business and software
growth
+3.3%
-0.7%
$81.2
Q2’25
17
2nd Quarter 2026
$80.6
Q2’26
$30.1
Adjusted
EBITDA
Margin:
$31.1
Q2’25
Q2’26
37.1%
38.6%
For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q2 2025 and Q2 2026 are to the three months ended June 30, 2025 and 2026, respectively.
1 Adjusted EBITDA Margin calculated as Adjusted EBITDA divided by Revenue.
Lower Nuclear Medicine
organic revenue due to
delayed hardware demand
Expanding margin
performance from price
and mix
Q2 2026
Earnings Presentation
Medical Segment Update
Adjusting End-market Organic Revenue Growth
Expectations; Maintaining Full Year Segment Guidance
RTQA1
Nuclear
Medicine
Dosimetry
18
1 Radiation Therapy Quality Assurance
‘26 Org. Revenue
Growth
Guidance:
Double Digits
previously MSD+
Increased revenue from OEM sector
‘26 Org. Revenue
Growth
Guidance:
Mid Single Digits
previously double digits
Reduced hardware volume due to delayed
demand; good order momentum in software
‘26 Org. Revenue
Growth
Guidance:
Negative
previously flat
Less hardware volume than expected;
Continued LSD+ service revenue growth
Q2 2026
Earnings Presentation
Adjusted Free Cash Flow
Best First Half Adjusted Free Cash Flow Since Going Public
EXPANDING ADJUSTED
FREE CASH FLOW
Adjusted Free Cash Flow & Conversion1
$ millions | % adj. EBITDA percentage
% Conversion
Expecting net working capital
tailwinds in H2’26
Adj. FCF
$60
51%
$35
Reflects capital structure
improvements implemented in 2025
& lower cash taxes
35%
(6%)
ON-TRACK FOR 2026
ADJUSTED FCF GUIDE
$4
5%
($5)
H1’23
19
H1’24
CAPITAL STRUCTURE
IMPROVEMENTS
H1’25
For a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures, please see the Appendix.
References to Q2 2025 and Q2 2026 are to the three months ended June 30, 2025 and 2026, respectively.
1 Adjusted Free Cash Flow conversion is calculated as Adjusted Free Cash Flow divided by Adjusted EBITDA.
H1’26
~$155 - $175 million of adjusted free
cash flow expected in 2026;
54 – 58% conversion
Q2 2026
Earnings Presentation
‘26 Guidance Reflects Strong Fundamentals
Reiterating full year guidance
FY 2026 Guidance1
TOTAL REVENUE
GROWTH
ORGANIC REVENUE
GROWTH
~22.0 – 24.0%
~5.0 – 7.0%
Includes FX and acquisitionrelated tailwinds
ADJUSTED FCF
Adjusted FCF Conversion
% of Adjusted EBITDA
ADJUSTED
EARNINGS PER SHARE2
~$155 – $175M
~$0.48 – $0.55
54% – 58%
per share
ADJUSTED
EBITDA
Margin %
~$285 – $300M
~25.0% – 26.0%
ANNUALIZED
FOREIGN EXCHANGE
SENSITIVITY3
+/- $3.5M
Revenue for every .01 ∆
+/- $1M
Adjusted EBITDA for every .01 ∆
20
1 2026 guidance includes an assumed second half foreign exchange rate of 1.14 Euro-to-USD,
Q2 2026
2 Includes interest expense savings from convertible notes and refinanced Term Loan B; interest income from incremental cash on the balance sheet; additional earnings from acquisitions; stock-based compensation.
Earnings
Presentation
3 Foreign exchange sensitivities are based on Euro exchange rates.
Setting the Stage for Second Half Acceleration
H2’26 performance expected to be markedly better than H1’26
Total Revenue Growth
FY Guidance: $1,129 - $1,147M
Organic Revenue Growth
Excl. FX & M&A impact
H1 2026
H2 2026
$524M
~$605M - $623M
+2.0%
~7.5% - 11.2%
FY Guidance: ~5.0 – 7.0%
Adjusted EBITDA %
% of total revenue
22.8%
~27% - 29%
$60M
~$95M - $115M
FY Guidance: ~25.0 – 26.0%
Adjusted FCF
FY Guidance: $155M – $175M
21
Driven by the Nuclear Power end-market within the Nuclear &
Safety segment and RTQA end-market within the Medical segment
+150 bps vs. H2’25
primarily due to operating leverage
Primarily reflects higher
Adjusted EBITDA and NWC tailwinds
Q2 2026
Earnings Presentation
Q3 2026 Guidance
Reflects accelerating revenue growth and strong operating leverage
CONSOLIDATED
NUCLEAR & SAFETY1
MEDICAL
Organic Revenue
Growth
Organic Revenue
Growth
Organic Revenue
Growth
vs. Q3’25
High Single Digit
High Single Digit
vs. Q3’25
(expecting double-digit Nuclear Power
end-market organic revenue growth)
vs. Q3’25
Adjusted EBITDA
Margin
Adjusted EBITDA
Margin
Adjusted EBITDA
Margin
Expanding
vs. Q3’25
Expanding
vs. Q3’25
22
Mid Single Digit
1 Nuclear & Safety segment includes Paragon.
Contracting
(reflecting Paragon dilution + ’25
lower incentive compensation)
vs. Q3’25
Q2 2026
Earnings Presentation
Appendix
23
1Q 2026
Q2
2025
Earnings Presentation
Organic Growth
Performance and Trends
NUCLEAR &
SAFETY
NUCLEAR POWER
LABS & RESEARCH
DEFENSE & DIVERSIFIED
INDUSTRIALS
2025 Organic
Growth
MSD
DD
Neg
HSD
LSD
2026E Organic
Growth
HSD
DD
FLAT
MSD
5.0 –
7.0%
NUCLEAR & SAFETY
END MARKET
Driven by
Nuclear
Power
MEDICAL
’26E ORGANIC
REVENUE GROWTH
2025 & 2026E
COMMENTARY & TRENDS
2025: New build and installed base driving
double-digit growth; SMR accelerating
•
2026E: SMR expected to be a bigger
contributing factor; new build & installed
base should demonstrate continued growth
•
2025: Negatively impacted by (1) delayed U.S.
DoE and Chinese demand; (2) government
shutdown; (3) and DOGE impacts.
•
2025: Double-digit industrials growth
partially offset by a tough comparable of
European civil defense revenue in 2024
•
2026E: Higher YTD; continued good dialogue
with customers but H2 timing remains
uncertain
•
2026E: Accelerated defense revenue
expected; tough comparable in diversified
industrials
END MARKET
MEDICAL
RADIATION THERAPY
QUALITY ASSURANCE (RTQA)
NUCLEAR MEDICINE
DOSIMETRY
2025 Organic
Growth
LSD
Neg
DD
LSD
2026E Organic
Growth
MSD
Previously
MSD+
2025 & 2026E
COMMENTARY & TRENDS
24
•
Previously
DD
Previously
FLAT
MSD
DD
•
2025: Hardware headwinds in N. America,
China, and Japan; partially offset by software
tailwinds
•
2026E: Increased revenue from OEM sector;
continued software platform growth; U.S.
hardware growth
Neg
•
2025: Hardware growth in the U.S. and RoW
supported by expansion of clinic growth
•
2025: Continued adoption of InstadoseVUE®;
timing headwind earlier in 2025
•
2026E: Reduced hardware growth due to
delayed demand; good order momentum in
software
•
2026E: Less hardware volume than expected;
Continued LSD+ service revenue growth
CANCER CARE
Q2 2026
Earnings Presentation
Non-GAAP Reconciliations
Adjusted Free Cash Flow and Net Leverage
($ millions)
1H
2024
1H
2025
1H
2026
Net cash provided by operating activities
$4.4
$21.2
$48.0
$77.4
Purchases of PPE and badges
(15.8)
(23.9)
(17.3)
(19.9)
Proceeds from derivative contracts
1.9
2.5
1.8
1.0
Cash used for non-operating expenses
4.6
4.6
2.1
1.4
$(4.9)
$4.4
$34.6
$59.9
Ending cash balance
$87
$122
$263
$419
Debt from first lien term loan
695
695
445
450
388
775
Net Debt
$608
$573
$570
$806
LTM Adjusted EBITDA
168
188
213
250
LTM Adjusted EBITDA Contribution from M&A
2
10
LTM Adjusted EBITDA Plus M&A Contribution
$168
$190
$213
$260
Total Net Debt / M&A Adjusted EBITDA (Net
Leverage)
3.6x
3.0x
2.7x
3.1x
Adjusted Free Cash Flow
Convertible Note
26
1H
2023
1 Assuming no M&A activity or capital raises.
▪ Cash Taxes: Lower cash taxes vs. H1’25
▪ Net Working Capital: Source of cash in Q2. Use of
cash in H1’26.
▪ Net Interest Expense: Reflects (1) reduced
interest expense from lower Term Loan B principal
partially offset by two convertible notes; and (2)
higher interest income from elevated cash held
from October 2025 capital raise to fund the
December 2025 acquisition of Paragon.
▪ Net Leverage: <2.5x expected by year-end1; in-line
with our long-term net leverage target.
Q2 2026
Earnings Presentation
Modeling Assumptions
Supporting 2026 Guidance
27
Amortization: (pre any incremental M&A)
~$118M; includes ~$25M associated with Paragon
Interest Expense:
Capex:
~$55M
Net Working Capital:
Cash Taxes:
~$30M
Stock-based Compensation:
~$26M
Effective Tax Rate:
~26 - 27%
Foreign Exchange Rate (EUR-to-USD):
1.14; second half 2026 assumption
Basic Share Count:
~244M shares
Diluted Share Count:
~273M shares; includes convertible notes
$450M SOFR + 2.00% for the ’32 Term Loan B;
$400M 0.25% ‘30 convert notes; $375M 0% ‘31 convert notes
use of cash; productivity metrics improving; more than offset by
project timing
Q2 2026
Earnings Presentation
Ten Quarter Segment Reconciliation
Nuclear & Safety
28
Q2 2026
Earnings Presentation
Ten Quarter Segment Reconciliation
Medical
29
Q2 2026
Earnings Presentation
Ten Quarter Segment Reconciliation
Corporate & Other
30
Q2 2026
Earnings Presentation
Ten Quarter Segment Reconciliation
Consolidated
31
Q2 2026
Earnings Presentation
Non-GAAP Reconciliations
Consolidated – Income from Operations, Gross Profit & Adjusted EBITDA
32
Q2 2026
Earnings Presentation
Non-GAAP Reconciliations
Adjusted Earnings per Share
33
1 The calculation for adjusted net income has been adjusted for the current period to include stock-based compensation.
Q2 2026
Earnings Presentation
Share Count
Details1
Outstanding Securities as
of 6/30/20262
Outstanding Securities as
of 12/31/20252
Shares of Class A Common Stock, including Treasury
Stock
249,078,209
248,155,411
Treasury Stock
(5,811,387)
(3,492,619)
Outstanding Shares of Class A Common Stock
243,266,822
244,662,792
Share Description
Shares of Class B Common Stock – Mirion
Management3
Illustrative Total Shares Outstanding
Convertible Notes
5,759,555
5,869,555
249,026,377
250,532,347
30,320,703
Notes
▪
Shares as of close of trading on the New York Stock Exchange (NYSE), including treasury stock
purchased by Mirion
▪
During the three months ended June 30, 2026, Mirion purchased 1.4 million shares of Class A
common stock as part of a share repurchase program.
▪
Outstanding shares as of close of trading on the New York Stock Exchange (NYSE), excluding
treasury stock
▪
Shares of Class B common stock are owned by certain current and former members of Mirion’s
management team and are paired on a one-for-one basis with shares of Class B common stock
of Mirion Intermediate Co, Inc. (the “paired interests”). Holders of the paired interests have the
right to have their interests redeemed for, at the option of Mirion, shares of Class A common
stock on a one-for-one-basis or cash based on a trailing stock price average.
▪
During the year ended December 31, 2025, Mirion issued $775 million of notes potentially
convertible to shares of Class A common stock (subject to the terms of the notes). The dilutive
impact shown is based upon an initial conversion rate of 43.2751 shares per $1,000 principal
amount of the May issuance ($400 million) and 34.6951 shares per $1,000 principal amount of
the September issuance ($375 million).
Mirion had 0.9 million shares of restricted stock units, 2.1 million shares of performance stock
units, and 2.5 million shares of performance stock options outstanding as of June 30, 2026.
Additionally, Mirion had reserved an additional 43.2 million shares of Class A common stock for
future equity awards issuance under its 2021 Omnibus Incentive Plan (subject to annual
automatic increases) as of June 30, 2026.
30,320,703
▪
Outstanding Equity Awards4
Total Illustrative Fully Diluted Shares
5,459,617
2,424,049
284,806,697
283,277,099
1 All data on this slide is as of June 30, 2026, or December 31, 2025, unless otherwise noted. All share numbers and dollar amounts are subject to adjustment for stock splits or other similar events.
2 This slide illustrates Mirion’s outstanding and fully diluted shares based on certain assumptions set forth in the “Notes” column and is designed to be illustrative and provide investors with additional information only. Different assumptions will yield
different results, and the actual number of our fully diluted shares in the future may differ significantly from those based on these assumptions. As a result, you should not rely on these forward-looking statements as predictions of future events. The
information provided is not presented in accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share (ASC 260) and does not represent a computation of weighted average shares nor are the numbers appropriate for calculating
Basic or Diluted EPS under ASC 260.
3 The slide illustrates the assumption that all of the paired interests will be redeemed and exchanged for shares of Class A common stock.
4 The number of reserved shares are subject to automatic increases on the first day of each year in an amount equal to the lesser of (i) three percent (3%) of the outstanding shares of Class A common stock on the last day of the immediately
preceding year, (ii) 9,976,164 shares of Class A common stock and (iii) such number of shares of Class A common stock as determined by Mirion Compensation Committee in its discretion.
34
Q2 2026
Earnings Presentation
Convertible Notes (Issued May and September 2025)
Illustrative Table of Potential Dilutive Impact of Convertible
Notes due 2030 & 2031 and Capped Call Overlay
Following table illustrates the potential dilutive shares under (i) our $400M aggregate principal amount of convertible notes due 2030 and (ii) our $375M aggregate
principal amount of convertible notes due 2031 (together, “the Notes”) that would be included in the calculation of our future reported GAAP EPS assuming various
hypothetical quarterly average market prices of our common stock (NYSE: MIR). The capped calls on each of the Notes are not included in the calculation of diluted
GAAP EPS as they are anti-dilutive. The Notes are expected to have a dilutive effect on GAAP EPS while outstanding, but the actual dilution at maturity is reduced by the
effects of our capped calls and upon an irrevocable election to net share settle the Notes
35
Note: This table is for illustrative purposes and does not represent our forecast of future stock performance
1 The prices listed in the table are illustrative. Although dilution continues beyond $60 per share, we have not presented further data
2 Assumes if-converted accounting, excludes offset of capped call (non-GAAP metric)
3 Assumes intent to net share settle convertible notes (treasury stock method accounting); includes offset of capped call (non-GAAP metric)
Q2 2026
Earnings Presentation
Footnotes
Share Count and Adjusted Metrics
Share count
243,266,822 shares of Class A common stock were outstanding as of June 30, 2026. This excludes (1) 5,759,555 shares of Class B common stock outstanding as of June 30, 2026, (2) 911,204 shares of Class A common
stock underlying restricted stock units, 2,048,413 shares of Class A common stock underlying performance stock units, and 2,500,000 shares of Class A common stock underlying performance stock options; and (3) any other
shares issuable from future equity awards under our 2021 Omnibus Incentive Plan, which had 52,609,685 shares reserved (subject to annual automatic increases) as of June 30, 2026. The 5,759,555 shares of Class B
common stock are paired on a one-for-one basis with shares of Class B common stock of Mirion Intermediate Co., Inc. (the "paired interests"). Holders of the paired interests have the right to have their interests redeemed for,
at the option of Mirion, shares of Class A common stock on a one-for-one basis or cash based on a trailing stock price average. All share data is as of June 30, 2026, unless otherwise noted.
Reconciliation of Non-GAAP Financial Measures
In addition to our results determined in accordance with GAAP, we believe the following non-GAAP measures are useful in evaluating our operating performance. We use the following non-GAAP financial information to
evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and
comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in
isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other
measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.
Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single
financial measure to evaluate our business.
Organic revenues is defined as revenues excluding the impact of foreign exchange rates as well as mergers, acquisitions and divestitures in the period.
Adjusted gross profit is defined as gross profit adjusted to exclude the impact of amortization of acquired intangible assets, depreciation, the impact of purchase accounting on the recognition of deferred revenue and certain
non-operating expenses (certain purchase accounting impacts related to inventory and costs to achieve operational synergies).
Adjusted EBITDA is defined as net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the impact of foreign currency gains and losses, amortization of acquired intangible
assets, changes in the fair value of warrants, certain non-operating expenses (restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses),
stock-based compensation expense, debt extinguishment and income tax impacts of these adjustments.
Adjusted net income is defined as GAAP net income adjusted for foreign currency gains and losses, amortization of acquired intangible assets, changes in the fair value of warrants, certain non-operating expenses
(restructuring and costs to achieve operational synergies, merger, acquisition and divestiture expenses and IT project implementation expenses), stock-based compensation expense (2025 and prior), debt extinguishment and
income tax impacts of these adjustments.
Adjusted EPS is as adjusted net income divided by weighted average common shares outstanding — basic and diluted.
Adjusted free cash flow is defined as free cash flow adjusted to include the impact of cash used to fund non-operating expenses described above. We believe that the inclusion of supplementary adjustments to free cash flow
applied in presenting adjusted free cash flow is appropriate to provide additional information to investors about our cash flows that management utilizes on an ongoing basis to assess our ability to generate cash for use in
acquisitions and other investing and financing activities.
Adjusted free cash flow conversion is defined as adjusted free cash flow divided by adjusted EBITDA.
Free cash flow is defined as U.S. GAAP net cash provided by operating activities adjusted to include the impact of purchases of property, plant, and equipment, purchases of badges and proceeds from derivative contracts.
Net leverage is defined as net debt (debt minus cash and cash equivalents) divided by Adjusted EBITDA plus contributions to Adjusted EBITDA if acquisitions made during the applicable period had been made before the start
of the applicable period.
Operating Metrics
Orders and Order growth are defined as the amount of revenue earned in a given period and estimated to be earned in future periods from contracts entered into in a given period as compared with such amount for a prior
period. Foreign exchange rates are based on the applicable rates for the time period.
36
Q2 2026
Earnings Presentation